Search

Gary P. Straub

Examiner (ID: 11985)

Most Active Art Unit
1103
Art Unit(s)
1103, 1754, 1106, 1801
Total Applications
1085
Issued Applications
776
Pending Applications
38
Abandoned Applications
271

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17749673 [patent_doc_number] => 20220227877 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/507895 [patent_app_country] => US [patent_app_date] => 2021-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33427 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17507895 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/507895
ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOF Oct 21, 2021 Abandoned
Array ( [id] => 18786127 [patent_doc_number] => 20230374140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => COMPOSITIONS TARGETING NDC80/MHC COMPLEXES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/247864 [patent_app_country] => US [patent_app_date] => 2021-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44043 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18247864 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/247864
COMPOSITIONS TARGETING NDC80/MHC COMPLEXES AND USES THEREOF Oct 7, 2021 Pending
Array ( [id] => 20562935 [patent_doc_number] => 12565536 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-03 [patent_title] => Method for generating avid-binding multispecific antibodies [patent_app_type] => utility [patent_app_number] => 17/488698 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 12191 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 283 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17488698 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/488698
Method for generating avid-binding multispecific antibodies Sep 28, 2021 Issued
Array ( [id] => 20715604 [patent_doc_number] => 12630843 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-19 [patent_title] => Polynucleotide for physiological expression in T-cells [patent_app_type] => utility [patent_app_number] => 18/246173 [patent_app_country] => US [patent_app_date] => 2021-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 3 [patent_no_of_words] => 5725 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246173 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/246173
Polynucleotide for physiological expression in T-cells Sep 20, 2021 Issued
Array ( [id] => 17704619 [patent_doc_number] => 20220204625 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => Combination Therapy for the Treatment of Cancer [patent_app_type] => utility [patent_app_number] => 17/479930 [patent_app_country] => US [patent_app_date] => 2021-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17479930 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/479930
Combination Therapy for the Treatment of Cancer Sep 19, 2021 Abandoned
Array ( [id] => 18693989 [patent_doc_number] => 20230324392 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS [patent_app_type] => utility [patent_app_number] => 18/043527 [patent_app_country] => US [patent_app_date] => 2021-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30436 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043527 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/043527
METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS Aug 31, 2021 Pending
Array ( [id] => 18690969 [patent_doc_number] => 20230321144 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => MODIFIED IMMUNE CELLS FOR FIBROSIS AND INFLAMMATION [patent_app_type] => utility [patent_app_number] => 18/023060 [patent_app_country] => US [patent_app_date] => 2021-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22669 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18023060 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/023060
MODIFIED IMMUNE CELLS FOR FIBROSIS AND INFLAMMATION Aug 26, 2021 Pending
Array ( [id] => 19311816 [patent_doc_number] => 12037619 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-16 [patent_title] => Angiotensin-converting enzyme 2 (ACE2) immunoadhesin microbody [patent_app_type] => utility [patent_app_number] => 17/405104 [patent_app_country] => US [patent_app_date] => 2021-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 17 [patent_no_of_words] => 13386 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17405104 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/405104
Angiotensin-converting enzyme 2 (ACE2) immunoadhesin microbody Aug 17, 2021 Issued
Array ( [id] => 17706006 [patent_doc_number] => 20220206012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS [patent_app_type] => utility [patent_app_number] => 17/393267 [patent_app_country] => US [patent_app_date] => 2021-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14801 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17393267 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/393267
METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS Aug 2, 2021 Pending
Array ( [id] => 20264153 [patent_doc_number] => 12435129 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Anti-Ab antibodies [patent_app_type] => utility [patent_app_number] => 17/383765 [patent_app_country] => US [patent_app_date] => 2021-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 49 [patent_no_of_words] => 19170 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17383765 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/383765
Anti-Ab antibodies Jul 22, 2021 Issued
Array ( [id] => 17368368 [patent_doc_number] => 20220023420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => FUSION CONSTRUCTS AND METHODS OF USING THEREOF [patent_app_type] => utility [patent_app_number] => 17/305577 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84669 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17305577 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/305577
Fusion constructs and methods of using thereof Jul 8, 2021 Issued
Array ( [id] => 18550783 [patent_doc_number] => 20230248783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => METHOD AND COMPOSITION FOR ENHANCING CANCER TREATMENT EFFICACY OF BACTERIA EXTRACELLULAR VESICLES [patent_app_type] => utility [patent_app_number] => 18/012498 [patent_app_country] => US [patent_app_date] => 2021-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7650 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18012498 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/012498
METHOD AND COMPOSITION FOR ENHANCING CANCER TREATMENT EFFICACY OF BACTERIA EXTRACELLULAR VESICLES Jun 21, 2021 Pending
Array ( [id] => 17399635 [patent_doc_number] => 20220041725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => Combination Therapy for the Treatment of Cancer [patent_app_type] => utility [patent_app_number] => 17/351724 [patent_app_country] => US [patent_app_date] => 2021-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17351724 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/351724
Combination Therapy for the Treatment of Cancer Jun 17, 2021 Abandoned
Array ( [id] => 20179509 [patent_doc_number] => 20250263467 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-21 [patent_title] => ANTIBODY THERAPIES FOR SARS-COV-2 INFECTION [patent_app_type] => utility [patent_app_number] => 18/001583 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -88 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001583 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/001583
ANTIBODY THERAPIES FOR SARS-COV-2 INFECTION Jun 10, 2021 Abandoned
Array ( [id] => 17297854 [patent_doc_number] => 20210393693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 17/342518 [patent_app_country] => US [patent_app_date] => 2021-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79137 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17342518 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/342518
T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof Jun 7, 2021 Pending
Array ( [id] => 19667564 [patent_doc_number] => 12180292 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => CD70 binding molecules and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/328118 [patent_app_country] => US [patent_app_date] => 2021-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 57 [patent_no_of_words] => 38265 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17328118 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/328118
CD70 binding molecules and methods of use thereof May 23, 2021 Issued
Array ( [id] => 18707643 [patent_doc_number] => 20230330222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => SELECTIVE TARGETING OF THE TREML1/MD2 INTERACTION BY SMALL PEPTIDE OR PROTEIN AND ITS USE FOR VACCINE ADJUVANTS [patent_app_type] => utility [patent_app_number] => 17/998733 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998733 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/998733
SELECTIVE TARGETING OF THE TREML1/MD2 INTERACTION BY SMALL PEPTIDE OR PROTEIN AND ITS USE FOR VACCINE ADJUVANTS May 13, 2021 Issued
Array ( [id] => 17067285 [patent_doc_number] => 20210269500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => CELL SURFACE COUPLING OF NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 17/318590 [patent_app_country] => US [patent_app_date] => 2021-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17318590 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/318590
Cell surface coupling of nanoparticles May 11, 2021 Issued
Array ( [id] => 19840178 [patent_doc_number] => 12252547 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same [patent_app_type] => utility [patent_app_number] => 17/317824 [patent_app_country] => US [patent_app_date] => 2021-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 108 [patent_figures_cnt] => 76 [patent_no_of_words] => 28186 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17317824 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/317824
Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same May 10, 2021 Issued
Array ( [id] => 17168805 [patent_doc_number] => 20210322475 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/307158 [patent_app_country] => US [patent_app_date] => 2021-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12556 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17307158 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/307158
COMPOSITIONS AND METHODS FOR TREATING CANCER May 3, 2021 Abandoned
Menu